mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ishikawa, Daisuke ^a,b   Takeuchi, Shinji ^a   Nakagawa, Takayuki ^a   Sano, Takako ^a   Nakade, Junya ^a   Nanjo, Shigeki ^a   Yamada, Tadaaki ^a   Ebi, Hiromichi ^a   Zhao, Lu ^a   Yasumoto, Kazuo ^a   Nakamura, Takahiro ^a   Matsumoto, Kunio ^a   Kagamu, Hiroshi ^b   Yoshizawa, Hirohisa ^b   Yano, Seiji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; S6 KINASE; SCATTER FACTOR; TEMSIROLIMUS; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL STRAIN HCC827; CELL STRAIN PC 9; CELL VIABILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877739371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062104     Document Type: Article

References (51)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
2. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
4. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, et al. (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28: 357-360.
5. Pao W, Chmielecki J, (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760-774.
6. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
7. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domein. PLoS Med 2: e73.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
9. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 174-183.
10. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, et al. (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutation. Cancer Res 68: 9479-9487.
11. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M, (2011) Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 73: 361-365.
12. Zakowski MF, Ladanyi M, Kris MG, (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355: 213-215.
13. Morinaga R, Okamoto I, Furuta K, Kawano Y, Sekijima M, et al. (2007) Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 58: 411-413.
14. Shiao TH, Chang YL, Yu CJ, Chang YC, Hsu YC, et al. (2008) Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14: 6092-6096.
15. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, et al. (2007) Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6: 1683-1691.
16. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, et al. (2010) Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 30: 2513-2517.
17. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, et al. (2011) Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6: 1152-1161.
18. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, et al. (2011) FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471: 523-526.
19. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, et al. (2011) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18: 74-82.
20. Zhang Z, Lee JC, Lin L, Olivas V, Au V, et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44: 852-860.
21. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, et al. (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6: 2011-2017.
22. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, et al. (2009) Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 15: 6630-6638.
23. Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, et al. (2012) Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 18: 1663-1671.
24. Takeuchi S, Wang W, Li Q, Yamada T, Kita K, et al. (2012) Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol 181: 1034-1043.
25. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, et al. (2012) Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 11: 2149-2157.
26. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, et al. (2011) Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17: 2260-2269.
27. Helena P, José ML, Paula S, (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci 13: 1886-1918.
28. Xiaodong F, William O, David H, (2010) Antiangiogenesis therapy: a new strategy for cancer treatment. US Pharm 35 (Oncology suppl):: 4-9.
29. Jayashree K, Amit M, (2011) PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4: 51.
30. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, et al. (2003) Regulation of hypoxia-inducible factor 1: expression and function by the mammalian target of rapamycin. Mol Cell 11: 1491-1501.
31. Takebayashi T, Iwamoto M, Jikko A, Matsumura T, Enomoto-Iwamoto M, et al. (1995) Hepatocyte growth factor/scatter factor modulates cell motility, proliferation, and proteoglycan synthesis of chondrocytes. J Cell Biol 129: 1411-1419.
32. Yano S, Takeuchi S, Nakagawa T, Yamada T, (2012) Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci 103: 1189-1194.
33. Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, et al. (2010) Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 16: 174-183.
34. Yasuda H, Kobayashi S, Costa DB, (2012) EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13: e23-31.
35. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
36. Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, et al. (2012) Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res 18: 3592-3602.
37. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504.
38. Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T, (2006) PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 1: 629-634.
39. Oh MH, Lee HJ, Yoo SB, Xu X, Choi JS, et al. (2012) Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch 460: 601-609.
40. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, et al. (2011) Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17: 2260-2269.
41. Yee Koh M, Spivak-Kroizman TR, Powis G, (2008) HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 33: 526-534.
42. Samy LH, Anamika Y, Lenin M, Anthony JV, (2011) Regulation of PI 3-K, PTEN, p53, and mTOR in malignant and benign tumors deficient in tuberin. Genes Cancer 2: 1051-1060.
43. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, et al. (2008) Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem 283: 16309-16319.
44. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246.
45. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
46. Ekman S, Wynes MW, Hirsch FR, (2012) The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J Thorac Oncol 7: 947-953.
47. Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-ZieglErk, Rowland KM, et al. (2012) Brief report: a phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol 7: 919-922.
48. Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, et al. (2012) Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 1: 1623-1629.
49. Leighl NB, Soria J, Bennouna J, Blais N, Traynor AM, et al. (2012) Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 28 (15 suppl):: 7524.
50. Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, et al. (2012) Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 7: 1594-1601.
51. Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, et al. (2012) Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Chemother Pharmacol 70: 707-716.